Aluminum, Calcium Or Magnesium Element, Or Compound Containing Patents (Class 424/682)
  • Publication number: 20130028985
    Abstract: Disclosed are compositions for treating or preventing migraine headaches and related headaches.
    Type: Application
    Filed: July 24, 2012
    Publication date: January 31, 2013
    Inventor: Donald J. Greene
  • Publication number: 20130028787
    Abstract: The present invention provides a sterilization auxiliary for ozone sterilization which is an aqueous solution including a Component (A) of an aluminum compound which produces aluminum ions in an aqueous solution, and a Component (B) of one or more of acids selected from phosphoric acid, citric acid, malic acid, succinic acid, gluconic acid, lactic acid, and L-tartaric acid, wherein the pH of the aqueous solution is greater than or equal to 1.0 and less than 5.0, and an ozone sterilization method for ozone-treating a substance to be treated using the sterilization auxiliary. According to the present invention, a sterilization auxiliary for ozone sterilization in which a high sterilizing effect may be obtained using less ozone without burdening sterilization apparatus and a substance to be treated, and a low-cost ozone sterilization method using the sterilization auxiliary can be provided.
    Type: Application
    Filed: April 7, 2011
    Publication date: January 31, 2013
    Applicant: LION CORPORATION
    Inventors: Yoshikuni Takeuchi, Sonoko Nishimura, Shinnichi Watanabe, Aiko Hayashi, Takayuki Hasegawa, Takayasu Kubozono
  • Publication number: 20130022673
    Abstract: Disclosed are methods and complexes for increasing magnesium uptake in mammals. Increasing magnesium uptake in mammals is accomplished by concurrently administering one or more magnesium salts with one or more quaternary amines and/or phosphatides and one or more di- or tri-carboxylic acids, in a one part dosage system or a multi-part dosage system. Increasing magnesium uptake in mammals may also be accomplished by concurrently administering one or more magnesium salts with an organic acid.
    Type: Application
    Filed: September 26, 2012
    Publication date: January 24, 2013
    Inventor: Russell Jaffe
  • Patent number: 8357696
    Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
    Type: Grant
    Filed: January 28, 2010
    Date of Patent: January 22, 2013
    Assignee: Mpex Pharmaceuticals, Inc.
    Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Rodny, David C. Griffith
  • Patent number: 8354126
    Abstract: The present invention provides an effective, all-natural, non-toxic, non-hormonal composition consisting of vitamin D3, vitamin E, selenium, green tea extract, saw palmetto berry extract, isoflavanoids, and lycopene for prostate health. The invention provides compositions and methods to prevent, alleviate, and/or treat symptoms associated with prostate conditions and diseases. The prostate health composition may be used to supplement medical treatment such as radiation therapy, chemotherapy, and hormone therapy.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: January 15, 2013
    Assignee: OncoNatural Solutions, Inc.
    Inventor: Jacek Pinski
  • Patent number: 8349376
    Abstract: A novel dietary supplement is featured which can benefit individuals suffering from various conditions such as nutritional deficiencies, vitamin deficiencies, aging, dementia/Alzheimer's disease, high blood pressure, high cholesterol, coronary artery disease, stroke and mental cognition.
    Type: Grant
    Filed: March 8, 2011
    Date of Patent: January 8, 2013
    Inventor: Mark S. Bezzek
  • Publication number: 20130004588
    Abstract: Compositions and methods for treating and/or preventing conditions such as diaper rash and atopic dermatitis are disclosed. The compositions and methods are particularly useful in the treatment and prevention of diaper rash and diaper dermatitis caused by the prolonged contact of human skin with body waste. The methods employ the topical application of a trypsin-inhibiting agent to the area in need of such treatment, or the area where prevention is desired. The trypsin-inhibiting agent is preferably a divalent cation.
    Type: Application
    Filed: June 28, 2011
    Publication date: January 3, 2013
    Inventors: Connie B. Lin, Euen Thomas Graham Ekman Gunn, Ya-Ping Hu, Neema Kulkarni, Mary Catherine Mack
  • Publication number: 20130004548
    Abstract: An embodiment of the present invention relates to a therapeutically active composition for the treatment of arteriosclerosis, and a pharmacological active agent-releasing medical device, the efficiency of which is increased by combination with a compound that releases alkaline-earth metal ions.
    Type: Application
    Filed: June 27, 2012
    Publication date: January 3, 2013
    Inventors: Bjoern Klocke, Laura Sager, Mathias Gratz
  • Patent number: 8343467
    Abstract: Glycopyrronium bromide, derivatives and/or isomers thereof in combination with one or more active substances selected from a list of substances as recited in the claims and/or in the form of a W/Si emulsion, an O/W gel, a soap gel stick, and/or a surfactant-containing cleansing formula, and corresponding cosmetic preparations, in particular deodorant/antiperspirant preparations.
    Type: Grant
    Filed: December 27, 2005
    Date of Patent: January 1, 2013
    Assignee: Beiersdorf AG
    Inventors: Michael Woehrmann, Lara Terstegen, Stefan Biel, Thomas Raschke, Svenja-Kathrin Cerv, Werner Zilz, Sven Untiedt, Thomas Nuebel, Uwe Schoenrock, Heiner Max, Helga Biergiesser, Yvonne Eckhard, Heike Miertsch, Heike Foelster, Cornelia Meier-Zimmerer, Bernd Traupe, Inge Kruse
  • Publication number: 20120328717
    Abstract: A pharmaceutical kit for treating neuronal damages is disclosed. The pharmaceutical composition of the present invention comprises: a first pharmaceutical composition comprising a first effective amount of a Mg2+-containing compound; and a second pharmaceutical composition comprising a second effective amount of a COX-2 inhibitor.
    Type: Application
    Filed: June 22, 2012
    Publication date: December 27, 2012
    Inventors: Kuen Jer TSAI, Liang Chao WANG
  • Patent number: 8338398
    Abstract: A composition for treating hearing loss includes components that function through different biological mechanisms to provide an additive effect that is equal to or greater than a sum of the effect of the individual components. The composition includes a biologically effective amount of at least one scavenger of singlet oxygen, a donor antioxidant, a third antioxidant, and a vasodilator. A method of treating hearing loss includes the step of internally administering the composition including a biologically effective amount of the at least one scavenger of singlet oxygen, the donor antioxidant, the third antioxidant, and the vasodilator to a mammal within three days of trauma to a middle or inner ear of the mammal.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: December 25, 2012
    Assignee: The Regents of the University of Michigan
    Inventors: Josef Miller, Colleen LePrell, Jochen Schact, Diane Prieskorn
  • Patent number: 8338397
    Abstract: A method of treating side effects of antibiotic treatment includes the step of internally administering an antibiotic that is capable of inducing hearing loss in a mammal. The method further includes the step of internally administering a composition to the mammal in conjunction with administration of the antibiotic. The composition includes a biologically effective amount of at least one scavenger of singlet oxygen, vitamin E, vitamin C, and a vasodilator comprising magnesium. The combination of vitamins and the vasodilator comprising magnesium, in the biologically effective amounts, provides an effective treatment for treating side effects of antibiotic treatment.
    Type: Grant
    Filed: April 15, 2010
    Date of Patent: December 25, 2012
    Assignee: The Regents of the University of Michigan
    Inventor: Josef Miller
  • Patent number: 8337904
    Abstract: A stable, phase-pure magnesium-substituted crystalline hydroxyapatite containing from about 2.0 to about 29 wt % magnesium, wherein at least 75 wt % of the magnesium content is substituted for calcium ions in the hydroxyapatite lattice structure.
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: December 25, 2012
    Assignees: Rutgers, The State University of New Jersey, Ethicon, Inc.
    Inventors: Richard E. Riman, Wojciech Suchanek, Pavel Shuk, Kevor S. TenHuisen, Chun-Wei Chen
  • Publication number: 20120315342
    Abstract: Disclosed is a composition containing a specific oligosaccharide and a bivalent metal cation, which exhibits an effect on the amelioration, treatment or prevention of allergy or topical inflammatory reactions in an extremely safe and effective manner compared to synthetic oral steroid medicines in spite of a fact that the composition contains components that are generally familiar as a food or an ion occurring in living bodies and have no toxicity against living bodies when used at physiological concentrations. Specifically disclosed is a cell-cell adhesion enhancer in epithelial cells, which comprises 1-kestose and/or nystose and a bivalent metal cation as active ingredients.
    Type: Application
    Filed: February 22, 2011
    Publication date: December 13, 2012
    Applicants: Tokai Medical Test Laboratory Co., B Food Science Co., Ltd., NichiNichi Pharmaceutical Co., Ltd.
    Inventors: Yasuhiro Koga, Yoshimitsu Suzuki, Satoshi Makishima, Kazuo Ogasa, Masayuki Suzuki, Toshiko Iizuka
  • Publication number: 20120301513
    Abstract: The present invention provides a pharmaceutical and/or veterinary composition comprising a retard release formulation of a Solarium glaucophyllum preparation. The composition further preferably comprises a calcium source. The composition of the invention is suitable to prevent and/or treat hypocalcaemia. Furthermore, the composition is suitable to prevent milk fever in cows. Advantageously, the composition is administered only once before calving so as to prevent the occurrence of milk fever in cows.
    Type: Application
    Filed: October 20, 2010
    Publication date: November 29, 2012
    Applicant: HERBONIS AG
    Inventors: Heinrich Bachmann, Walter Rambeck
  • Patent number: 8313754
    Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of two polymers that have a synergistic effect on viscosity.
    Type: Grant
    Filed: April 11, 2011
    Date of Patent: November 20, 2012
    Assignee: Novartis AG
    Inventors: Masood A. Chowhan, Huagang Chen
  • Publication number: 20120288573
    Abstract: A method is provided for preventing or treating bone or musculoskeletal metabolism disorders or kidney malfunction in humans. It comprises providing to a subject in need of that a calcium containing or calcium enriched diet combined with the administration of an efficient amount of a plant extract of Solatium glaucophyllum comprising from about 0.8 to about 2.2 weight % of a mixture of 1,25-dihydroxyvitamin D3 glycosides and quercetin glycosides present in a ratio of about 1:100 to 1:200 parts by weight. There are also provided food or dietary composition and food supplement designed for preventing or treating bone or musculoskeletal metabolism disorders or kidney malfunction in humans which comprises an efficient amount of the said plant extract of Solanum glaucophyllum and a source of calcium.
    Type: Application
    Filed: October 20, 2010
    Publication date: November 15, 2012
    Applicant: HERBONIS AG
    Inventors: Heinrich Bachmann, Sabrina Autzen
  • Patent number: 8309080
    Abstract: Metallo-proteins including but not limited to lactoferrin (LF), transferrin (TF) and ovotransferrin (OTF) (all members of transferrin family), ceruloplasmin (CP) and metallo-thionein (MT) were found to stabilize and enhance the bio-functional activity of tocotrienol (T3), T3 mixtures or derivates. The synergism between MP and T3 also promote the intestinal transfer and the ultimate bio-availability of T3 and T3-derivatives for physiological functions. Such functional synergism includes hypocholesterolemic, anti-thrombotic, antioxidant, anti-athermogenic, anti-inflammatory and immuno-regulatory activities of T3 agents. These T3 compositions are useful as pharmaceuticals, in cosmetics, in foods and as nutritional supplements.
    Type: Grant
    Filed: December 3, 2008
    Date of Patent: November 13, 2012
    Assignee: Naidu LP
    Inventors: A. Satyanarayan Naidu, A. G. Sreus Naidu, A. G. Tezus Naidu
  • Publication number: 20120282352
    Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.
    Type: Application
    Filed: July 9, 2012
    Publication date: November 8, 2012
    Applicant: CYPRESS PHARMACEUTICAL, INC.
    Inventors: Robert L. Lewis, Charles E. Day
  • Publication number: 20120282235
    Abstract: Embodiments of the present invention include a surgical kit for preparation of a patch for implantation into a human body, characterized in that it comprises a package containing, on one hand, a synthetic substrate (1) and, on the other hand, means for treatment of the substrate with a solution (3) including at least one biologically active component (4, 5), adapted to integrate the biologically active component with the substrate. Embodiments of the invention include a patch for implantation into the human body, comprising a synthetic substrate (1), characterized in that at least one biologically active component (4, 5) is integrated with the substrate using the surgical kit.
    Type: Application
    Filed: June 1, 2010
    Publication date: November 8, 2012
    Inventors: Kevin L. Ohashi, Dale R. Peterson, Jamal Rushdy
  • Patent number: 8298588
    Abstract: An improved dietary and/or therapeutic supplement composition comprising a quantity of a dietary and/or therapeutic supplement agent having a pH that upon ingestion with food or a beverage would limit the effectiveness of the agent and a sufficient amount of an alkaline electrolyte additive is provided in combination with the agent to raise the pH of the composition to a level of from about 8 to about 12.5 to increase the effectiveness and functional utilization of the agent while the composition is in the person's stomach. The supplement composition is designed to provide for optimum utilization of a dietary and/or therapeutic supplement agent when taken orally with food or a beverage.
    Type: Grant
    Filed: April 11, 2008
    Date of Patent: October 30, 2012
    Inventors: Janmarie Hornack, Lawrence E. Dorman
  • Publication number: 20120269869
    Abstract: A colon vitamin includes ingredients that are delivered to different regions of the digestive tract. A first group of ingredients which can include: vitamin D, folic acid, vitamin B2, vitamin B6, beta-carotene, selenium, curcumin, green tea extract, and a portion of the calcium serving can be in a first delivery mechanism that releases these ingredients in the stomach. A second delivery mechanism is used to deliver elemental calcium intact through the stomach and small intestine to the large intestine. The delivery of the ingredients to specific areas of the digestive tract reduces the risk of colorectal adenomatous polyps and colorectal cancers.
    Type: Application
    Filed: April 23, 2012
    Publication date: October 25, 2012
    Inventor: Frank J. Farrell
  • Publication number: 20120258156
    Abstract: Shaped compositions are provided for use in delivering a substantially uniform concentration of a functional agent (e.g., an antimicrobial sanitizing agent) to a flowing stream of water. The composition may be shaped and sized to be inserted into a device configured to be attached over the end of a faucet. The shaped composition may include at least two different regions (e.g., layers). A dissolvable region includes a functional agent (e.g., an anti-microbial sanitizing agent). A substantially non-dissolvable region is disposed adjacent to the dissolvable region (e.g., adjacent the bottom surface) so as to cover a bottom surface of the dissolvable region. The geometry of the shaped composition, as well as the presence of the substantially non-dissolvable region aids in providing a substantially uniform concentration of functional agent throughout the life of the dissolvable region.
    Type: Application
    Filed: March 22, 2012
    Publication date: October 11, 2012
    Inventors: EVAN RUMBERGER, William Ouellette, William L. Smith, Tami Tadrowski
  • Patent number: 8282965
    Abstract: The invention pertains to a liquid composition for preventing and/or treating memory decline and/or cognitive dysfunction, Alzheimer's, Parkinson's and/or dementia, said composition comprising: (i) at least 50 mg nucleoside and/or nucleotide per 100 ml; (ii) between 0.2 and 10 grams protein per 100 ml; (iii) between 0.05 and 3 wt. % of 5 thickener, based on total weight of the composition. The thickener is preferably selected from the group consisting of cellulose, xanthan gum, gellan gum, alginate, guar gum, locust bean gum, gum karaya, gum tragacanth, carrageenan, and mixtures thereof. The composition preferably has a loss factor tan ? between 0.1 and 100, as measured at any strain in the range of 1 100% at 0.1 Hz and 20° C. It is particularly found that a thickener selected from the group consisting of gellan gum, xanthan gum and cellulose greatly reduces sedimentation.
    Type: Grant
    Filed: March 4, 2008
    Date of Patent: October 9, 2012
    Assignee: N.V. Nutricia
    Inventors: Esther Jacqueline de Kort, Robert Johan Joseph Hageman, Martine Groenendijk, Patrick Joseph Gerardus Hendrikus Kamphuis
  • Publication number: 20120253298
    Abstract: A tissue thickness compensator may generally comprise a first layer comprising a first medicament, a second layer comprising a second medicament, and a third layer comprising a third medicament. The tissue thickness compensator may comprise a first layer comprising a first medicament, a second layer comprising a second medicament, and a reservoir comprising a third medicament disposed within the reservoir. The medicaments may be independently selected from a haemostatic agent, an anti-inflammatory agent, an antibiotic agent, anti-microbial agent, an anti-adhesion agent, an anti-coagulant agent, a pharmaceutically active agent, a matrix metalloproteinase inhibitor, and combinations thereof. Articles of manufacture comprising the tissue thickness compensator and methods of making and using the tissue thickness compensator are also described.
    Type: Application
    Filed: March 28, 2012
    Publication date: October 4, 2012
    Applicant: Ethicon Endo-Surgery, Inc.
    Inventors: Cortney E. Henderson, Taylor W. Aronhalt, Chunlin Yang, Charles J. Scheib, Venkataramanan Mandakolathur Vasudevan, Mark D. Timmer, Richard W. Timm, Tamara Widenhouse, Steven G. Hall
  • Publication number: 20120251632
    Abstract: The invention provides a method of improving one or more clinical outcomes of an individual experiencing an acute respiratory attack. The acute respiratory attack may include acute reversible bronchospasm, severe acute bronchospasm, or acute exacerbation of asthma. The method includes administering to an individual suffering from an acute respiratory attack an effective amount of bedoradrine or a pharmaceutically acceptable salt thereof in combination with a standard of care (SOC) treatment regimen.
    Type: Application
    Filed: June 15, 2012
    Publication date: October 4, 2012
    Inventors: Kazuko MATSUDA, Yuichi Iwaki, Kirk W. Johnson
  • Patent number: 8277829
    Abstract: A biocompatible inorganic porous material having a three-dimensional coexistent network of interconnected macro-pores and nanopores produced by the steps of mixing an organic water-soluble polymer (e.g., polyethylene oxide or a block copolymer of ethylene oxide and propylene oxide), an alkoxysilane, and an inorganic water-soluble calcium salt in an aqueous acid solution, such that a sol-gel process of hydrolysis and polycondensation is initiated and thereby producing a gel; drying the gel to remove solvent by evaporation; and heating the gel to remove the polymer by thermal decomposition, thereby forming an inorganic porous material, which may be suitable for use as a bone tissue scaffold.
    Type: Grant
    Filed: August 30, 2007
    Date of Patent: October 2, 2012
    Assignee: Lehigh University
    Inventors: Himanshu Jain, Ana C. Marques, Rui M. Almeida
  • Publication number: 20120244224
    Abstract: A method of inducing mineralization in a bone cell is described. The method comprises contacting a bone cell with a composition comprising nanoparticles. The nanoparticles can be single-walled carbon nanotubes, hydroxyapatite nanoparticles, TiO2 nanoparticles or silver nanoparticles. The bone cell can be an osteoblast cell. A method for increasing bone mass, bone healing or bone formation is also described which comprises administering to a subject in need thereof an effective amount of a composition comprising nanoparticles. The subject can suffer from a bone disease such as osteoporosis. The subject can suffer from a bone fracture and the method can comprise contacting bone cells near the bone fracture site with the composition. The composition can further comprise a pharmaceutically acceptable carrier.
    Type: Application
    Filed: March 21, 2012
    Publication date: September 27, 2012
    Applicant: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
    Inventors: Alexandru S. BIRIS, Daniel CASCIANO, Meena Waleed MAHMOOD
  • Publication number: 20120244232
    Abstract: Black bear parathyroid hormone (PTH) and functional fragments thereof are provided. Also provided are methods of using black bear PTH and functional fragments for increasing cAMP in a bone-forming cell; reducing apoptosis in a bone-forming cell; decreasing the ratio of expression levels of Bax protein to Bcl-2 protein in a bone-forming cell; increasing the expression level of one or more of a bone matrix protein, a transcriptional activator, or a transcriptional regulator in a bone-forming cell; enhancing bone mineral density, increasing bone mass, decreasing bone loss, or reducing the incidence of bone fractures, or any combination thereof, in a subject; also provided are antibodies directed against black bear parathyroid hormone (PTH) and functional fragments thereof.
    Type: Application
    Filed: December 7, 2009
    Publication date: September 27, 2012
    Applicant: MICHIGAN TECHNOLOGICAL UNIVERSITY
    Inventor: Seth W. Donahue
  • Patent number: 8273380
    Abstract: A beverage for minimizing or reducing jet lag symptoms preferably includes vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin D, zinc, calcium, iodine, magnesium, manganese, ginseng, ginkgo biloba, grape seed extract, Echinacea extract and water. A method for minimizing or reducing jet lag symptoms including ingestion of the beverage by a traveler, one hour prior to a flight, and/or during the flight, and/or after a flight.
    Type: Grant
    Filed: May 19, 2009
    Date of Patent: September 25, 2012
  • Patent number: 8273383
    Abstract: Methods and compositions for treating and/or preventing a pregnancy related disease or disorder are provided. The methods involve administration of 2-methoxyestradiol, or an analog thereof, to a subject. Also provided are methods for diagnosing or predicting a pregnancy related disease or disorder. The methods involve detection of 2-methoxyestradiol, or a precursor or metabolite thereof.
    Type: Grant
    Filed: May 4, 2005
    Date of Patent: September 25, 2012
    Assignees: Children's Medical Center Corporation, Beth Israel Deaconess Medical Center
    Inventors: Judah Folkman, Raghu Kalluri
  • Publication number: 20120237617
    Abstract: Methods of treating a subject who has an tissue damage or who is at risk for tissue necrosis are disclosed. Also disclosed are methods of treating a subject who has an inflammatory disorder. The methods can include administering to the subject a pharmaceutical composition comprising inorganic nitrite or a pharmaceutically acceptable salt thereof, for a time and in an amount sufficient to reduce the tissue damage. The subject can be diagnosed as having a medical condition that results tissue damage, for example, diabetes, peripheral artery disease, cardiovascular disease, defective wound healing, arthritis, inflammatory bowel disease, ischemia, or a bacterial infection, e.g., Group A staphylococcal infection. The methods can include the step of monitoring the course of treatment.
    Type: Application
    Filed: May 26, 2010
    Publication date: September 20, 2012
    Applicant: TheraVasc Inc.
    Inventor: Christopher Kevil
  • Publication number: 20120237570
    Abstract: The present invention relates to methods and compositions for reducing distress dysfunction, including emotional and physical distress. The invention entails co-administration of at least one Receptor Switcher and at least one Endorphin Enhancer. Additionally, at least one Synergistic Enhance and/or at least one Exogenous Opioid are also administered to enhance or prolong the therapeutic effects.
    Type: Application
    Filed: April 30, 2012
    Publication date: September 20, 2012
    Inventors: Steven Crain, William E. Crain, Stanley M. Crain, Michael Crain
  • Patent number: 8263667
    Abstract: A nutritional supplement for use in physiologically stressful conditions is disclosed. The nutritional supplement may include one or more of vitamin A, vitamin E, vitamin D3, vitamin C, vitamin B1, riboflavin, niacin, folic acid, vitamin B6, biotin, pantothenic acid, vitamin B12, magnesium, zinc, selenium, chromium, copper, iron, alpha lipoic acid, lutein and lycopene.
    Type: Grant
    Filed: March 8, 2011
    Date of Patent: September 11, 2012
    Assignee: Vertical Pharmaceuticals, Inc.
    Inventors: Steven A. Squashic, Kevin M Hudy, David C. Purdy
  • Patent number: 8257750
    Abstract: Compositions and methods for inhibiting gastrointestinal absorption of phosphate in a subject are provided. Such compositions are composed of enteric-coated, sustained-release calcium carbonate, which find application in the prevention or treatment of hyperphosphatemia.
    Type: Grant
    Filed: July 30, 2008
    Date of Patent: September 4, 2012
    Assignee: Kibow Biotech, Inc.
    Inventor: Natarajan Ranganathan
  • Patent number: 8257721
    Abstract: An oral care product comprising a source of calcium ions, a source of phosphate ions, and an insoluble whitening agent for deposition onto the teeth, characterized in that the source of calcium ions and the source of phosphate ions are physically separate prior to the use of the product.
    Type: Grant
    Filed: December 4, 2007
    Date of Patent: September 4, 2012
    Assignee: Conopco, Inc.
    Inventors: Michael Francis Butler, Yan Deng, Mary Heppenstall-Butler, Andrew Joiner, Haiyan Li, Xiaoke Li
  • Patent number: 8252344
    Abstract: A composition for promoting the formation of clots in blood comprises a zeolite and a binder. The zeolite is adjusted to have a specific moisture content. Processes by which the moisture content is adjusted include drying, re-hydrating, and combinations of drying and re-hydrating. A method of forming the composition comprises the steps of providing a zeolite and adjusting the moisture content such that upon application of the composition to a wound, a heat of hydration is reduced and heat transferred to the wound is reduced. A method of clotting blood flowing from a wound comprises the steps of applying the zeolite to the wound and maintaining the zeolite in contact with the wound for a predetermined amount of time, the zeolite having an adjusted moisture content and being capable of producing a controllable exothermic effect on the wound.
    Type: Grant
    Filed: September 13, 2004
    Date of Patent: August 28, 2012
    Assignee: Z-Medica Corporation
    Inventor: Francis X. Hursey
  • Patent number: 8247000
    Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.
    Type: Grant
    Filed: April 10, 2009
    Date of Patent: August 21, 2012
    Assignee: Cypress Pharmaceutical, Inc.
    Inventors: Robert L. Lewis, Charles E. Day
  • Patent number: 8241671
    Abstract: In order to provide a biocompatible material consisting mainly of a fish scale-derived hydroxyapatite and a fish scale-derived collagen, which is adjusted so that easily digested and absorbed in a human body, the material contains a composite consisting mainly of a fish scale-derived hydroxyapatite and a fish scale-derived collagen.
    Type: Grant
    Filed: October 22, 2008
    Date of Patent: August 14, 2012
    Assignee: RBS Co., Inc.
    Inventor: Yoshiaki Okada
  • Patent number: 8236358
    Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and an enteric coating.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: August 7, 2012
    Assignee: Cypress Pharmaceutical, Inc.
    Inventors: Robert L. Lewis, Charles E. Day
  • Publication number: 20120195873
    Abstract: Nutritional compositions and methods of using the nutritional compositions with exercise to attenuate the loss of functional status are provided. In a general embodiment, the present disclosure provides a nutritional composition including whey protein, and Vitamin D. The nutritional composition and exercise can be specifically used to attenuate the loss of functional status, especially in the elderly.
    Type: Application
    Filed: July 15, 2010
    Publication date: August 2, 2012
    Applicant: NESTEC S.A.
    Inventors: Kevin Burke Miller, Ingo Arne Jurk, Zamzam Kabiry Roughead
  • Publication number: 20120195979
    Abstract: The present invention is directed to a treatment composition for recreational water, comprising a high molecular weight water soluble resin composition made from long chain alkoxylated polymers or co-polymers that impart emollient properties to the recreational water, as well as articles of manufacture comprising packaging material and the treatment composition for recreational water contained within the packaging material. The present invention is also directed to methods for treating recreational water, and recreational water treated with the above treatment composition.
    Type: Application
    Filed: April 13, 2012
    Publication date: August 2, 2012
    Applicant: ARCH CHEMICALS, INC.
    Inventors: Derek Francis PARISH, Christopher M. ZETENA
  • Publication number: 20120189709
    Abstract: Disclosed are methods of treating an individual having a condition characterized by an imbalance in type 1 and type 2 cytokine production, wherein the method comprises administering to the individual an amount of ?-hydroxy-?-methylbutyrate (HMB) effective to modulate or otherwise cause an increase in the ratio of type 1 to type 2 cytokines, including an increase in the ratio of type 1 to type 2 cytokines without a corresponding increase in type 2 cytokine levels. Also disclosed are methods of using HMB to treat asthma and allergies. The methods of the present invention are based upon the discovery that HMB modulates cytokine production, most typically by increasing type 1 cytokines without a corresponding increase in type 2 cytokines.
    Type: Application
    Filed: January 11, 2012
    Publication date: July 26, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Debra L. Thomas, Pradip Mukerji
  • Publication number: 20120181230
    Abstract: The invention relates to the production of a concentrate for dialysis, the composition of which can be adapted individually to the respective needs of the patient. To do so, the special components required individually are added in the form of highly concentrated special concentrates with a volume of 10-500 mL to 3-10 liters of standard concentrate. The two solutions are then mixed thoroughly by compressed air, which is blown through the concentrate intake rod into the solution from a compressed air source in the dialysis machine.
    Type: Application
    Filed: January 9, 2012
    Publication date: July 19, 2012
    Inventor: Peter Kloeffel
  • Publication number: 20120177744
    Abstract: Disclosed are methods of treating an individual having a condition characterized by an imbalance in type 1 and type 2 cytokine production, wherein the method comprises administering to the individual an amount of ?-hydroxy-?-methylbutyrate (HMB) effective to modulate or otherwise cause an increase in the ratio of type 1 to type 2 cytokines, including an increase in the ratio of type 1 to type 2 cytokines without a corresponding increase in type 2 cytokine levels. Also disclosed are methods of using HMB to treat asthma and allergies. The methods of the present invention are based upon the discovery that HMB modulates cytokine production, most typically by increasing type 1 cytokines without a corresponding increase in type 2 cytokines.
    Type: Application
    Filed: January 11, 2012
    Publication date: July 12, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Debra L. Thomas, Pradip Mukerji
  • Patent number: 8216172
    Abstract: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolytes but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: July 10, 2012
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Peter C. Chang, Jean-Michel Lannoy
  • Patent number: 8216614
    Abstract: A composition comprising a powder mixture of potassium citrate and calcium citrate as mixtures of pure chemical salts and methods of making and using the composition are disclosed. The composition is useful for the treatment and prevention of kidney stones and osteoporosis and better delivers potassium and calcium than commonly used potassium and calcium supplements.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: July 10, 2012
    Assignee: The Board of Regents of the University of Texas Systems
    Inventors: Charles Y. C. Pak, Khashayar Sakhaee, Neill B. Walsdorf, Sr.
  • Publication number: 20120171307
    Abstract: A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.
    Type: Application
    Filed: February 22, 2012
    Publication date: July 5, 2012
    Applicant: Magceutics, Inc.
    Inventors: Guosong Liu, Fei Mao
  • Publication number: 20120171130
    Abstract: A composition is able to treat plant and animal diseases and includes a therapeutically effective amount of an encapsulated ionic mineral complex and a pharmaceutically acceptable carrier. The composition may also include other inert ingredients, botanical extracts and vitamin and mineral supplements.
    Type: Application
    Filed: October 31, 2007
    Publication date: July 5, 2012
    Inventor: John Wayne Kennedy
  • Patent number: 8211417
    Abstract: A method is disclosed for cleansing bowels prior to a colonic procedure utilizing conventional preparations along with potatoes.
    Type: Grant
    Filed: October 31, 2009
    Date of Patent: July 3, 2012
    Inventor: Harry Snady